360Dx

Qiagen, DiaSorin Partner to Automate Latent TB Testing

Jan 08, 2018

NEW YORK (360Dx) – Qiagen and DiaSorin announced today that they are working together to pair Qiagen's QuantiFeron-TB diagnostic test with DiaSorin's Liaison family of automated analyzers.

Customers of both companies will now be able to process Qiagen's QuantiFeron-TB Gold Plus (QFT-Plus) assay for latent tuberculosis detection on DiaSorin Liaison platforms, in addition to the standard current workflow. The companies noted that there are more than 7,000 Liaison systems in laboratories worldwide.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Qiagen, DiaSorin Partner to Automate Latent TB Testing

To read the full story....

Breaking News

Guardant Health Q4 Revenues Up 25 Percent

Adaptive Biotechnologies Q4 Revenues Rise 25 Percent

CareDx Q4 Revenues Up 64 Percent

Walgreens to Sell Labcorp COVID-19 PCR Home Collection Kits Over-the-Counter

Qiagen, Inovio Expand CDx Partnership, Starting With NGS Test for Cervical Dysplasia Therapy

NeoGenomics Q4 Revenue Grows 18 Percent, CEO to Retire

Featured White Papers

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

What's Popular?

Meridian Withdraws Emergency Use Authorization Application to FDA for Coronavirus MDx Test

Siemens Healthineers Obtains CE Mark for Laboratory-Based, High-Throughput Antigen Test

SARS-CoV-2 Test Pooling Studies Offer Insights for Implementing, Optimizing Approaches

Following IPO, Ortho Clinical Diagnostics to Invest in R&D, Keep Pace With Competitors

Cue Health Nabs CE Mark for Molecular Point-of-Care COVID-19 Test

Sponsorships